EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Malin's Enterprise Value is $-35.00 Mil.
Malin's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.30 Mil. Therefore, Malin's EV-to-EBIT for today is 26.97.
The historical rank and industry rank for Malin's EV-to-EBIT or its related term are showing as below:
MLLNF's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 15.81 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Malin's Enterprise Value for the quarter that ended in Dec. 2024 was $56.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Malin's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malin EV-to-EBIT Related Terms
Malin EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Malin's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Malin's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malin EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Malin's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Malin's EV-to-EBIT falls into.
Malin's current Enterprise Value is $-35.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Malin's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malin (MLLNF) has a EV-to-EBIT of 26.97 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Malin and its competitors.
Is Malin's EV-to-EBIT too high?
Malin's current EV-to-EBIT is 26.97. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Malin's value of 26.97 is 70.6% above this industry median. Overall, Malin has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Malin's EV-to-EBIT compare to ZTS and UTHR?
Malin's EV-to-EBIT of 26.97 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.81. Malin's value of 26.97 is 70.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Malin's current EV-to-EBIT of 26.97 is 70.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Malin and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malin's current EV-to-EBIT is 26.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (MLLNF) has a current EV-to-EBIT of 26.97. The current EV-to-EBIT is 26.97 and 70.6% above the Drug Manufacturers industry median of 15.81. Malin's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Malin (MLLNF), the current EV-to-EBIT is 26.97 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.
17GF Score
Get the complete analysis for MLLNF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLNF has been successfully added to your 
